Compositions and methods of treating muscular dystrophy with thromboxane-A2 receptor antagonists
US10064845B2 · kind B2 · utility
1Cited by
18References
22Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | May 11, 2017 |
| Grant date | Sep 4, 2018 |
| Priority date | — |
| Expiry date | May 11, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P21/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to methods of treating and/or ameliorating muscular dystrophy and/or treating cardiomyopathy in muscular dystrophy patients by administration of a therapeutically effective amount of a thromboxane A2 receptor antagonist.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.